Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice Infestation

A Safety and Pharmacokinetic Study of Ha44 Gel Administered Topically Under Maximal Use Conditions for the Treatment of Head Lice Infestation.

The purpose of the study is to evaluate the safety and tolerability of a single application of Ha44 Gel 0.74% w/v for the treatment of head lice under maximal use conditions.

Secondary objective is to evaluate pharmacokinetics of Ha44 and benzyl alcohol (contained in Ha44 vehicle) under maximal use conditions.

Study Overview

• Status: Completed
• Conditions: Head Lice Infestation
• Intervention / Treatment: Drug: Ha44 Gel

Detailed Description

This is an open-label safety and pharmacokinetic (PK) study involving a single application of Ha44 Gel 0.74% administered under maximal use conditions.

All participants must have an active head lice infestation (at least 3 live lice) and be 6 months to 17 years of age. The study will enroll approximately 36 pediatric subjects between the ages of 6 months and 17 years.

Pediatric PK samples will be collected at 0 (predose), 30 and 60 mins and 2 and 8 hrs time points.

More than one household member with an active lice infestation may participate in the study. Eligible subjects will be consented and screened for study eligibility on Day 0 (Visit 1). All subjects will return to the study site for three follow-up clinic visits at Days 1, 7 and 14. The maximum study duration for a subject is 16 days.

• Study Type: Interventional
• Enrollment (Actual): 38
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 months to 17 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or female
2. 6 months to 17 years of age
3. Be in good health, as determined by medical history and physical examination
4. Has an active head lice infestation at screening as determined by an experienced evaluator. An active infestation is defined as the presence of at least 3 live lice.

5. Female subjects must be:

   • Of non-childbearing potential (no history of menstrual periods, post-hysterectomy, or post-menopausal for at least 2 years) OR,
   • If of childbearing potential, must have a negative urine pregnancy test prior to treatment and agree to use a highly effective method of contraception from Day 0 through the Day 14 visit. Acceptable methods of contraception include abstinence, vasectomized partner, tubal ligation, combined oral hormonal contraceptive, contraceptive injection, contraceptive patch, or IUD. If a hormonal contraception is the only method, the subject must have been on a stable dose for at least 3 months.
6. The parent/guardian agrees to allow serial blood samples collected from subject for PK analysis during study.
7. Has signed an informed consent and/or assent form (ICF).

Exclusion Criteria:

1. Has a condition or illness that, in the opinion of the Investigator, may interfere with the study results.
2. Has current dermatological disease or inflammation on the face, scalp, ears, neck or back, including eczema, atopic dermatitis, alopecia, psoriasis or any other chronic skin disease that, in the opinion of the Investigator, would interfere with the safety or PK evaluation.
3. Had a prior reaction to products containing piperonyl butoxide, pyrethrin, or pyrethrum extract.
4. Has been using hormonal contraception for less than 3 months.
5. Is pregnant or currently nursing.
6. Receiving systemic or topical medication, which in the opinion of the Investigator, may interfere with the study results.
7. Has received an investigational agent within 30 days prior to Day 0.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1; Ha44 Gel 0.74%, topical solution, maximum feasible amount applied for 10 minutes	Drug: Ha44 Gel; Eligible subjects will be treated at the study site on Day 0 with a single application of the maximum feasible amount of Ha44 Gel, to ensure saturation of the scalp and hair.; Other Names: Benzyl Alcohol

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of the Subjects With AEs.	Safety and tolerability assessed by AEs. Number of subjects with reporting AEs.	3 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pk Parameters: Cmax	Maximum concentration of Ha44 (Cmax)	0 to 8 hours
PK Parameters: Tmax	Time to maximum concentration of Ha44 (Tmax)	0-8 hours
PK Parameters: AUC(0-8)	Area under the concentration-time curve of Ha44 (AUC 0-8)	0-8 hours

Collaborators and Investigators

• Sponsor: Dr. Reddy's Laboratories Limited
• Collaborators: Target Health Inc.; Accelovance

Study record dates

Study Major Dates

• Study Start: March 1, 2013
• Primary Completion (Actual): July 1, 2013
• Study Completion (Actual): December 1, 2013

Study Registration Dates

• First Submitted: July 22, 2013
• First Submitted That Met QC Criteria: July 24, 2013
• First Posted (Estimate): July 25, 2013

Study Record Updates

• Last Update Posted (Actual): April 28, 2020
• Last Update Submitted That Met QC Criteria: April 20, 2020
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Keywords: Topical treatment of Head Lice Infestation
• Additional Relevant MeSH Terms: Skin Diseases; Infections; Ectoparasitic Infestations; Skin Diseases, Parasitic; Skin Diseases, Infectious; Lice Infestations; Parasitic Diseases; Mite Infestations; Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Sensory System Agents; Anesthetics; Anesthetics, Local; Benzyl Alcohol
• Other Study ID Numbers: Ha03-004

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO